Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324078 | 0.98 | TP53 (0.62) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL23704649 | 0.87 | — | — | |
| SCHEMBL15415082 | 0.87 | — | — | |
| SCHEMBL8503062 | 0.86 | TP53 (0.61) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL6227823 | 0.85 | TP53 (0.64) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5185757 | 0.85 | TP53 (0.64) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL14463100 | 0.85 | TP53 (0.64) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL133228 | 0.80 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5228082 | 0.80 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL4079339 | 0.80 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60262893-A | — | — | None | — | — | JP | disclosed |
| EP-3835302-A1 | DIISOCYANATE COMPOUND HAVING ANHYDROSUGAR ALCOHOL CORE AND PREPARATION METHOD THEREFOR | Samyang Corporation (KR) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020032611-A1 | DIISOCYANATE COMPOUND HAVING ANHYDROSUGAR ALCOHOL CORE AND PREPARATION METHOD THEREFOR | 주식회사 삼양사 | 2020-02-13 | — | — | WO | disclosed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| EP-1973917-A2 | PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
| JP-S60262893-A | WATER-SOLUBLE CUTTING OIL | YUSHIRO DO BRAZIL IND CHEM LTD | 1985-12-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | TP53 22/4885KDM4E 2024/4885GMNN 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.